c. Moody’s Investors Service downgraded the long-term senior unsecured rating of AZN from A1 to Aa2 in 2007. Assess any potential association between this downgrade and AZN’s arrangements with Merck. Paris‚ July 30‚ 2007 -- Moody’s Investors Service downgraded the long-term senior unsecured ratings of AstraZeneca plc and its guaranteed subsidiary to A1 from Aa2. This downgrade followed the announcement of AstraZeneca’s acquisition of MedImmune for a total consideration of more than US$15 billion
Premium Money
Merck‚ being on one of the biggest pharmaceutical companies in the world today‚ came from a meek beginning and still encounters many problems today while trying to maintain a lead amongst its competition. While being looked at as a research and development driven company‚ Merck now has to go beyond R&D to stay competitive in the pharmaceutical industry. Attracting talent to work for the company has never been a problem for Merck‚ but the bigger question was whether or not this talent would be able
Premium Pharmaceutical industry Pharmacology Generic drug
BUAD820 – Case 2 Merck Case Decision Tree and Analysis Presented By – Sridevi Chennuri Nuray Coban Subhashini Reddy Merck & Company :Evaluating a Drug Licensing Opportunity • Background - Merck & Company : •In 2000‚ it was a global research-driven pharmaceutical company that discovers‚ develop‚ manufactures and markets a broad range of human and animal health products‚ directly and through its joint ventures‚ and provides pharmaceutical benefit management services through Merck-Medco Managed Care
Premium Clinical trial Decision tree Expected value
Merck was at the top of the pharmaceutical market for many years. The company made substantial profits almost every year. Not only were they a company that made money but they also made their financial gains in an ethical manor. Fourton magazine even named them the “most admired” company. But in 2004‚ the company would be faced with major challenges that would threaten to end the company’s existence. Their once best selling painkiller Viol had been recalled by the federal government because the drug
Premium Pharmacology Pharmaceutical industry
Merck and Co. and river blindness MANUEL VELASQUEZ‚ Business Ethics. Concepts and cases 4th edt.‚ Prentice Hall‚ Upper Saddle River‚ New Jersey‚ 1998 River blindness is an agonizing disease that affects some 18 million impoverished people living in remote villages along the banks of rivers in tropical regions of Africa and Latin America. The disease is caused by a tiny parasitic worm that is passed from person to person by the bite of the black fly which breeds in river waters. The tiny worms
Premium Pharmaceutical industry Ethics Drug discovery
Business and Professional Ethics MERCK AND THE MARKETING OF VIOXX – CASE ANALYSIS Questions 1) What are the highlights of the case? 2) What are the ethical issues in the case? 3) What the ethical theories evidenced in the case? 4) How would you resolve the problem? What are the ethical issues in the case? In identifying the issue(s) we first have to identify the level in which this business is operating. Merck & Company was a top‚ well respected pharmaceutical company in America
Premium Ethics
Questions for the Merck Case Create a decision tree for Merck. The 2 leftmost branches would identify the alternatives related to licensing Davarink (specifically license versus not to license). Next‚ if Merck decides to pursue license‚ they go into phase I which results in a success‚ or failure. Phase I success is followed by phase II where Merck has the opportunity to develop the drug to treat depression alone‚ weight loss alone‚ or both‚ or contemplate phase II failure. Finally phase
Premium Decision tree Decision theory
Executive Summary Merck & Company has been presented with an opportunity to invest $30 million for the purchasing rights of an obesity and high cholesterol lowering drug‚ KL-798 from Kappa Labs. Based on the expected probabilities of success through each product-development phase for this new drug‚ as well as the costs involved‚ the net present value of the project is -$1.16 million and is therefore recommended that Merck passes on the investment. Sensitivity analysis also show that adjusting
Premium Clinical trial Net present value Investment
Merck & Co.‚ Inc (A) (The summary is based on the article in Vol. I and does not include the extra readings given by the professor) This case is a classic example of enterprises trying to balance their business of increasing profits and expected social responsibilities. This dilemma is further accentuated when the company happens to be a pharma company whose decisions directly affect people’s lives. The Dilemma: A possible drug for River Blindness‚ a disease which affects almost 85 million
Premium Pharmacology Medicine Affect
A Discussion on the Company’s Decision Making Process‚ Group Behavior and Organizational Structure Abstract Merck is a pharmaceutical and medical researching company that is dealing with managerial challenges in their daily business operations. Their background and their issues regarding the matter will then help one understand how the actual picture of the real accounts of the managerial decision processes that happen to actual multinational company operations. Having been
Premium Corporation Business Company